Cribriform morphology is associated with higher risk of biochemical recurrence after radical prostatectomy in patients with Grade Group 5 prostate cancer.


Journal

Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136

Informations de publication

Date de publication:
Jun 2023
Historique:
revised: 14 02 2023
received: 12 01 2023
accepted: 23 02 2023
medline: 17 5 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

Grade Group 5 (GG5) prostate cancer (PCa) is associated with a high risk of disease recurrence after radical prostatectomy (~75% at 5 years). However, this is a heterogeneous category that includes neoplasms with different combinations of Gleason pattern (GP) 4 and 5. Within GP4, large cribriform growth has been associated with adverse disease-specific outcomes in GG2-4 PCa. Less is known about the significance of cribriform morphology and the different histologic patterns of GP5 in GG5 PCa. In this study we evaluated the prognostic implications of cribriform morphology (either invasive or intraductal, henceforth "cribriform") and large solid growth or comedonecrosis (comedo/solid) in patients with GG5 PCa. One-hundred and thirty prostatectomies from a single institution were analysed. The presence of comedo/solid components was associated with a higher frequency of concurrent cribriform PCa (85.7% versus 45.9%, P < 0.001), lymphovascular invasion (44.6% versus 27%, P = 0.04), and biochemical recurrence (48.2% versus 28.4%, P = 0.03). The presence of large cribriform growth was associated with a higher frequency of extraprostatic involvement (i.e. pT3a-b; 85.3% versus 68.7%, P = 0.02), positive surgical margins (47.6% versus 29.2%, P = 0.04) and biochemical recurrence (47.6% versus. 18.7%, P = 0.001). Kaplan-Meier analysis demonstrated that GG5 PCa with cribriform or comedo/solid components had a higher probability of biochemical recurrence. Multivariable analysis showed that only cribriform components were an independent predictor of a higher risk of biochemical recurrence in this series. These findings highlight the importance of reporting the presence of cribriform components in GG5 PCa and suggest that cribriform morphology might help decide postsurgical management in these patients.

Identifiants

pubmed: 36939057
doi: 10.1111/his.14901
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1089-1097

Informations de copyright

© 2023 John Wiley & Sons Ltd.

Références

Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013; 111; 753-760.
Epstein JI, Zelefsky MJ, Sjoberg DD et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason Score. Eur. Urol. 2016; 69; 428-435.
Kweldam CF, Kümmerlin IP, Nieboer D et al. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. Mod. Pathol. 2017; 30; 1126-1132.
Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJLH. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod. Pathol. 2015; 28; 457-464.
Hollemans E, Verhoef EI, Bangma CH et al. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Mod. Pathol. 2021; 34; 184-193.
Seyrek N, Hollemans E, Osanto S et al. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients. Histopathology 2022; 80; 558-565.
Kweldam CF, Kümmerlin IP, Nieboer D et al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod. Pathol. 2016; 29; 630-636.
Chua MLK, Lo W, Pintilie M et al. A prostate cancer “Nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies. Eur. Urol. 2017; 72; 665-674.
Iczkowski KA, Torkko KC, Kotnis GR et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am. J. Clin. Pathol. 2011; 136; 98-107.
Elfandy H, Armenia J, Pederzoli F et al. Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate. Mol. Cancer Res. 2019; 17; 446-456.
Böttcher R, Kweldam CF, Livingstone J et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 2018; 18; 8.
Acosta AM, Al Rasheed MRH, Rauscher GH et al. Tumor necrosis in radical prostatectomies with high-grade prostate cancer is associated with multiple poor prognostic features and a high prevalence of residual disease. Hum. Pathol. 2018; 75; 1-9.
Hollemans E, Verhoef EI, Bangma CH et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod. Pathol. 2019; 32; 139-146.
Chan E, McKenney JK, Hawley S et al. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for “large” cribriform prostatic adenocarcinoma. Mod. Pathol. 2022; 35; 1092-1100.
Haffner MC, Weier C, Xu MM et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J. Pathol. 2016; 238; 31-41.
Hansum T, Hollemans E, Verhoef EI et al. Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients. Mod. Pathol. 2021; 34; 2064-2070.
Flood TA, Schieda N, Sim J et al. Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer. Virchows Arch. 2018; 472; 205-212.
van Royen ME, Verhoef EI, Kweldam CF et al. Three-dimensional microscopic analysis of clinical prostate specimens. Histopathology 2016; 69; 985-992.

Auteurs

Jihane Oufattole (J)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Tanujit Dey (T)

Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Anthony V D'Amico (AV)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Geert J L H van Leenders (GJLH)

Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.

Andres M Acosta (AM)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH